Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.
Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A. Boileau JF, et al. Among authors: basik m. J Clin Oncol. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1. J Clin Oncol. 2015. PMID: 25452445 Clinical Trial.
"I just wanted more": Hereditary cancer syndromes patients' perspectives on the utility of circulating tumour DNA testing for cancer screening.
Adi-Wauran E, Clausen M, Shickh S, Gagliardi AR, Denburg A, Oldfield LE, Sam J, Reble E, Krishnapillai S, Regier DA, Baxter NN, Dawson L, Penney LS, Foulkes W, Basik M, Sun S, Schrader KA, Karsan A, Pollett A, Pugh TJ; CHARM consortium; Kim RH, Bombard Y. Adi-Wauran E, et al. Among authors: basik m. Eur J Hum Genet. 2024 Feb;32(2):176-181. doi: 10.1038/s41431-023-01473-y. Epub 2023 Oct 11. Eur J Hum Genet. 2024. PMID: 37821757
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, Basik M. Hassan S, et al. Among authors: basik m. Int J Cancer. 2011 Jul 1;129(1):225-32. doi: 10.1002/ijc.25665. Epub 2010 Nov 12. Int J Cancer. 2011. PMID: 20830712 Free article.
Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes.
Tabariès S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, Basik M, Bertos N, Park M, Guettier C, Adam R, Hallett M, Siegel PM. Tabariès S, et al. Among authors: basik m. Oncogene. 2011 Mar 17;30(11):1318-28. doi: 10.1038/onc.2010.518. Epub 2010 Nov 15. Oncogene. 2011. PMID: 21076473
Imiquimod in the treatment of breast cancer skin metastasis.
Henriques L, Palumbo M, Guay MP, Bahoric B, Basik M, Kavan P, Batist G. Henriques L, et al. Among authors: basik m. J Clin Oncol. 2014 Mar 10;32(8):e22-5. doi: 10.1200/JCO.2012.46.4883. Epub 2014 Jan 13. J Clin Oncol. 2014. PMID: 24419128 No abstract available.
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.
Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M. Aguilar-Mahecha A, et al. Among authors: basik m. Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28. Mod Pathol. 2017. PMID: 28752846 Free article. Clinical Trial.
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J. Savage P, et al. Among authors: basik m. Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015. Cell Rep. 2017. PMID: 29091754 Free article.
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF. Goyette MA, et al. Among authors: basik m. Cell Rep. 2018 May 1;23(5):1476-1490. doi: 10.1016/j.celrep.2018.04.019. Cell Rep. 2018. PMID: 29719259 Free article.
121 results